company background image
PIRS logo

Pieris Pharmaceuticals Informe acción NasdaqCM:PIRS

Último precio

US$16.98

Capitalización de mercado

US$22.8m

7D

-0.1%

1Y

-19.6%

Actualizada

04 Nov, 2024

Datos

Finanzas de la empresa

Pieris Pharmaceuticals, Inc.

Informe acción NasdaqCM:PIRS

Capitalización de mercado: US$22.8m

Resumen de acción PIRS

Pieris Pharmaceuticals, Inc. es una empresa biotecnológica que descubre y desarrolla aplicaciones biotecnológicas.

Análisis fundamental de PIRS
Puntuación del snowflake
Valoración2/6
Crecimiento futuro0/6
Rendimiento pasado0/6
Salud financiera4/6
Dividendos0/6

Competidores de Pieris Pharmaceuticals, Inc.

Historial de precios y rendimiento

Resumen de todos los máximos históricos, cambios y caídas de precios de Pieris Pharmaceuticals
Precios históricos de las acciones
Precio actual de la acciónUS$16.98
Máximo en las últimas 52 semanasUS$23.20
Mínimo de 52 semanasUS$6.20
Beta0.67
1Cambio en 1 mes4.44%
Variación en 3 meses2.12%
Cambio de 1 año-19.59%
3Variación en 3 años-94.88%
Variación en 5 años-94.63%
Variación desde la OPV-91.84%

Noticias y actualizaciones recientes

The Market Doesn't Like What It Sees From Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Revenues Yet As Shares Tumble 30%

Jul 11
The Market Doesn't Like What It Sees From Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Revenues Yet As Shares Tumble 30%

Why Investors Shouldn't Be Surprised By Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) 27% Share Price Plunge

Apr 21
Why Investors Shouldn't Be Surprised By Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) 27% Share Price Plunge

Recent updates

The Market Doesn't Like What It Sees From Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Revenues Yet As Shares Tumble 30%

Jul 11
The Market Doesn't Like What It Sees From Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Revenues Yet As Shares Tumble 30%

Why Investors Shouldn't Be Surprised By Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) 27% Share Price Plunge

Apr 21
Why Investors Shouldn't Be Surprised By Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) 27% Share Price Plunge

We Think Pieris Pharmaceuticals (NASDAQ:PIRS) Needs To Drive Business Growth Carefully

Mar 19
We Think Pieris Pharmaceuticals (NASDAQ:PIRS) Needs To Drive Business Growth Carefully

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Not Doing Enough For Some Investors As Its Shares Slump 27%

Dec 18
Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Not Doing Enough For Some Investors As Its Shares Slump 27%

We Think Pieris Pharmaceuticals (NASDAQ:PIRS) Needs To Drive Business Growth Carefully

Aug 18
We Think Pieris Pharmaceuticals (NASDAQ:PIRS) Needs To Drive Business Growth Carefully

Analysts Just Shaved Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Forecasts Dramatically

May 15
Analysts Just Shaved Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Forecasts Dramatically

Why Investors Shouldn't Be Surprised By Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) 41% Share Price Plunge

Apr 17
Why Investors Shouldn't Be Surprised By Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) 41% Share Price Plunge

Can Pieris Pharmaceuticals (NASDAQ:PIRS) Afford To Invest In Growth?

Dec 31
Can Pieris Pharmaceuticals (NASDAQ:PIRS) Afford To Invest In Growth?

Bearish: This Analyst Is Revising Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Revenue and EPS Prognostications

Aug 10
Bearish: This Analyst Is Revising Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Revenue and EPS Prognostications

Pieris Pharmaceuticals GAAP EPS of -$0.14 misses by $0.03, revenue of $3.7M misses by $6.77M

Aug 04

Pieris: Early Stage Developer Of Novel Asset Class

Jan 09

We're Not Very Worried About Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Rate

Dec 15
We're Not Very Worried About Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Rate

Progress At Pieris Pharmaceuticals

Oct 27

Analysts Just Made A Noticeable Upgrade To Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Forecasts

Aug 05
Analysts Just Made A Noticeable Upgrade To Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Forecasts

We Think Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) CEO Compensation Package Needs To Be Put Under A Microscope

Jun 19
We Think Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) CEO Compensation Package Needs To Be Put Under A Microscope

Need To Know: Analysts Just Made A Substantial Cut To Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Estimates

May 22
Need To Know: Analysts Just Made A Substantial Cut To Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Estimates

Will Pieris Pharmaceuticals (NASDAQ:PIRS) Spend Its Cash Wisely?

May 19
Will Pieris Pharmaceuticals (NASDAQ:PIRS) Spend Its Cash Wisely?

Analysts Are Betting On Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) With A Big Upgrade This Week

Apr 01
Analysts Are Betting On Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) With A Big Upgrade This Week

Here's What Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Shareholder Ownership Structure Looks Like

Mar 08
Here's What Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Shareholder Ownership Structure Looks Like

We're Keeping An Eye On Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Rate

Feb 01
We're Keeping An Eye On Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Rate

How Much Did Pieris Pharmaceuticals'(NASDAQ:PIRS) Shareholders Earn From Share Price Movements Over The Last Three Years?

Dec 28
How Much Did Pieris Pharmaceuticals'(NASDAQ:PIRS) Shareholders Earn From Share Price Movements Over The Last Three Years?

How Does Pieris Pharmaceuticals' (NASDAQ:PIRS) CEO Salary Compare to Peers?

Dec 02
How Does Pieris Pharmaceuticals' (NASDAQ:PIRS) CEO Salary Compare to Peers?

Rentabilidad de los accionistas

PIRSUS BiotechsMercado US
7D-0.1%-1.4%-1.9%
1Y-19.6%20.2%30.4%

Rentabilidad vs. Industria: Los resultados de PIRS fueron inferiores a los de la industria US Biotechs, que obtuvo un rendimiento del 20.2% el año pasado.

Rentabilidad vs. Mercado: PIRS obtuvo unos resultados inferiores a los del mercado US, que fueron del 30.4% el año pasado.

Volatilidad de los precios

Is PIRS's price volatile compared to industry and market?
PIRS volatility
PIRS Average Weekly Movement6.0%
Biotechs Industry Average Movement9.6%
Market Average Movement6.0%
10% most volatile stocks in US Market15.0%
10% least volatile stocks in US Market2.9%

Precio estable de las acciones: PIRS no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de PIRS ha disminuido de 16% a 6% en el último año.

Acerca de la empresa

FundadaEmpleadosCEOPágina web
200148Steve Yoderwww.pieris.com

Pieris Pharmaceuticals, Inc. es una empresa biotecnológica que descubre y desarrolla aplicaciones biotecnológicas. La empresa se centra en el desarrollo de sus programas inmuno-oncológicos (IO) de biespecíficos 4-1BB. Sus proyectos clínicos consisten en IO biespecíficos, incluido S095012 (PRS-344), un compuesto biespecífico de Mabcalin dirigido a PD-L1 y 4-1BB en asociación con Les Laboratoires Servier y el Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), un compuesto biespecífico de anticuerpo-Anticalin CD228 x 4-1BB dirigido a CD228 y 4-1BB en asociación con Pfizer Inc

Resumen de fundamentos de Pieris Pharmaceuticals, Inc.

¿Cómo se comparan los beneficios e ingresos de Pieris Pharmaceuticals con su capitalización de mercado?
Estadísticas fundamentales de PIRS
Capitalización bursátilUS$22.84m
Beneficios(TTM)-US$23.82m
Ingresos (TTM)US$20.87m

1.1x

Ratio precio-ventas (PS)

-0.9x

Ratio precio-beneficio (PE)

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de PIRS
IngresosUS$20.87m
Coste de los ingresosUS$16.02m
Beneficio brutoUS$4.85m
Otros gastosUS$28.67m
Beneficios-US$23.82m

Últimos beneficios comunicados

Jun 30, 2024

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)-18.04
Margen bruto23.26%
Margen de beneficio neto-114.11%
Ratio deuda/patrimonio0%

¿Cómo se ha desempeñado PIRS a largo plazo?

Ver rendimiento histórico y comparativa